Advanced Filters
noise

Syracuse, New York Clinical Trials

A listing of Syracuse, New York clinical trials actively recruiting patient volunteers.

Found 154 clinical trials
J Jonathan Preston, PhD

Evaluating the Effectiveness of Hybrid and Traditional Speech Therapy for /ɹ/ and /s/ Sound Production

The purpose of this research study is to evaluate the effectiveness of a hybrid Artificial Intelligence-assisted speech therapy model, which combines the use of an AI speech therapist (Jessica) with traditional speech therapy sessions led by a Speech-Language Pathologist (SLP). This study aims to determine whether the hybrid model improves …

5 - 17 years of age All Phase N/A
G Genesis Guzman

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

18 years of age All Phase 2

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. Pemvidutide: 2.4 mg SC once weekly Placebo: Placebo SC once weekly

18 - 75 years of age All Phase 2
B Benedette Herbst

Treatment for /s/ Production Errors in Children With Speech Sound Errors

We want to learn about a new way to help people make the /s/ sound, like in the word "snake." We will be studying a way to teach the /s/ sound that uses very short speech sessions. This study will also collect recordings from people as they say words with …

7 - 11 years of age All Phase N/A

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

18 - 70 years of age All Phase 1/2
E Elaine R Hitchcock, PhD

Visual-acoustic Intervention With Service Delivery In-person and Via Telepractice Trial

Children with speech sound disorder show diminished intelligibility in spoken communication and may thus be perceived as less capable than peers, with negative consequences for both socioemotional and socioeconomic outcomes. New technologies have the potential to transform interventions for speech sound disorder, but there is a lack of rigorous evidence …

9 - 17 years of age Female Phase 2
E Elaine R Hitchcock, PhD

Generalization With AI Navigation Using StaRt

Speech Sound Disorder (SSD) affects a significant portion of school-aged children, leading to social and emotional challenges that can persist into adolescence and adulthood. The number of productions necessary for a remediated speech sound to generalize to connected speech is challenging to achieve in practice, leading clinicians to call for …

9 - 17 years of age All Phase 2
J Joe Kucksdorf Physical Therapy Supervisor - Emplify, DPT, DScPT

Validating a Clinical Prediction Rule to Guide Manual Therapy and Exercise for Neck Pain Relief

Neck pain is a common issue that can lead to long-term disability and lost work time for many individuals. Despite numerous studies, finding effective treatment strategies has been challenging. One possible reason for this is that treatments may not have been tested on the specific groups of people who would …

18 - 70 years of age All Phase N/A
H Hazani Benitez-Rosas

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.

18 - 75 years of age All Phase 1/2

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

55 - 90 years of age All Phase 2

Simplify language using AI